股本结构
单位：万股
| 公告日期 | 2025-06-16 | 2025-05-20 | 2025-04-11 | 2024-11-12 | 2024-08-15 | 2024-04-25 |
|---|---|---|---|---|---|---|
| 证券总股本 | 22517.27 | 22515.94 | 22515.59 | 22433.83 | 22431.40 | 22430.57 |
| 普通股本 | 22517.27 | 22515.94 | 22515.59 | 22433.83 | 22431.40 | 22430.57 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-06-10 | 2025-03-31 | 2025-03-15 | 2024-09-30 | 2024-06-30 | 2024-03-15 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-06-16 | 22517.27 | 未披露 | 定期报告 | 2025-06-10 |
| 2025-05-20 | 22515.94 | 未披露 | 定期报告 | 2025-03-31 |
| 2025-04-11 | 22515.59 | 未披露 | 定期报告 | 2025-03-15 |
| 2024-11-12 | 22433.83 | 未披露 | 定期报告 | 2024-09-30 |
| 2024-08-15 | 22431.40 | 未披露 |
更多>>
From January 1, 2024 to June 30, 2024
Settlement of share-based payment awards
|
2024-06-30 |
| 2024-04-25 | 22430.57 | 未披露 | 定期报告 | 2024-03-15 |
| 2024-04-25 | 22398.87 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Shares issued as part of the at-the-market offering program
Shares issued as part of the public offering
Shares issued for LTIP option exercises and RSU releases
|
2023-12-31 |
| 2023-11-14 | 22392.37 | 未披露 | 定期报告 | 2023-09-30 |
| 2023-08-17 | 22388.31 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-05-30 | 22385.15 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-02-09 | 22198.13 | 未披露 |
更多>>
common shares offered 27,027,028 shares by the company
|
2023-02-10 |
| 2023-04-25 | 19495.42 | 未披露 |
更多>>
From January 1, 2022 to December 31, 2022
Issuance of share capital (net of transaction costs)
Share issuances and contingent consideration from business combination
Exercise of options / Settlement of share-based payment awards
|
2022-12-31 |
| 2022-11-17 | 19028.32 | 未披露 | 定期报告 | 2022-09-30 |
| 2022-08-18 | 18746.70 | 未披露 | 定期报告 | 2022-06-30 |
| 2022-05-25 | 18712.07 | 未披露 | 定期报告 | 2022-03-31 |
| 2022-04-28 | 18703.11 | 未披露 | 定期报告 | 2022-03-22 |
| 2022-04-28 | 18712.07 | 未披露 |
更多>>
From January 1, 2021 to December 31, 2021
Exercise of options
Issuance of share capital (net of transaction costs)
|
2021-12-31 |
| 2021-12-17 | 18705.26 | 未披露 | 定期报告 | 2021-09-30 |
| 2021-09-17 | 18682.92 | 未披露 | 定期报告 | 2021-06-30 |
| 2021-04-27 | 18659.98 | 未披露 | 定期报告 | 2021-04-10 |
| 2021-02-04 | 18691.35 | 未披露 |
更多>>
1.The company is offering 5,000,000 common shares.
2.Unless otherwise indicated, all information contained in this prospectus is based on 181,163,480 common shares outstanding as of December 31, 2020.
3.CureVac N.V. (Nasdaq: CVAC) (“CureVac” or the “Company”) announced today that the underwriters of its previously announced public offering, which closed on February 1, 2021, have exercised in full their option to purchase an additional 750,000 of its common shares at the public offering price of $90.00 per common share, less underwriting discounts and commissions.
|
2021-02-01 |
| 2021-04-27 | 18046.06 | 未披露 |
更多>>
from January 1, 2020 to December 31, 2020
Exercise of options
Issuance of share capital (net of transaction costs)
|
2020-12-31 |
| 2021-01-25 | 18036.80 | 未披露 | 定期报告 | 2020-09-30 |
| 2020-08-14 | 17596.82 | 未披露 |
更多>>
1.Common shares offered 13,333,333 common shares.
|
2020-08-14 |
From January 1, 2024 to June 30, 2024
Settlement of share-based payment awards
From December 31, 2022 to December 31, 2023
Shares issued as part of the at-the-market offering program
Shares issued as part of the public offering
Shares issued for LTIP option exercises and RSU releases
common shares offered 27,027,028 shares by the company
From January 1, 2022 to December 31, 2022
Issuance of share capital (net of transaction costs)
Share issuances and contingent consideration from business combination
Exercise of options / Settlement of share-based payment awards
From January 1, 2021 to December 31, 2021
Exercise of options
Issuance of share capital (net of transaction costs)
1.The company is offering 5,000,000 common shares.
2.Unless otherwise indicated, all information contained in this prospectus is based on 181,163,480 common shares outstanding as of December 31, 2020.
3.CureVac N.V. (Nasdaq: CVAC) (“CureVac” or the “Company”) announced today that the underwriters of its previously announced public offering, which closed on February 1, 2021, have exercised in full their option to purchase an additional 750,000 of its common shares at the public offering price of $90.00 per common share, less underwriting discounts and commissions.
from January 1, 2020 to December 31, 2020
Exercise of options
Issuance of share capital (net of transaction costs)
1.Common shares offered 13,333,333 common shares.